Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacoeconomic evaluation of COPD.

D E Hilleman1, N Dewan, M Malesker

  • 1Department of Pharmacy Practice, Creighton University School of Pharmacy and Allied Health Professions, Omaha, NE 68178, USA.

Chest
|November 18, 2000
PubMed
Summary

The cost of treating chronic obstructive pulmonary disease (COPD) increases with disease severity. Specific bronchodilator therapies, like ipratropium or ipratropium plus a ss-agonist, can lower overall COPD treatment costs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter.

Drugs of today (Barcelona, Spain : 1998)·2003
Same author

Comparison of 24-hour blood pressure profiles in patients with hypertension who were switched from amlodipine to nisoldipine.

Pharmacotherapy·2001
Same author

Physician-prompting statin therapy intervention improves outcomes in patients with coronary heart disease.

Pharmacotherapy·2001
Same author

Potential influence of timing of low-density lipoprotein cholesterol evaluation in patients with acute coronary syndrome.

Pharmacotherapy·2001
Same author

Diagnostic and prognostic value of Holter-detected ST-segment deviation in unselected patients with chest pain referred for coronary angiography: a long-term follow-up analysis.

Chest·2001
Same author

Efficacy and safety of a therapeutic interchange from high-dose calcium channel blockers to a fixed-dose combination of amlodipine/benazepril in patients with moderate-to-severe hypertension.

Journal of human hypertension·2001

Area of Science:

  • Pulmonary Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Chronic obstructive pulmonary disease (COPD) is a significant health burden with varying clinical outcomes and associated healthcare costs.
  • Understanding the economic impact of COPD based on disease severity and treatment is crucial for resource allocation and cost-effective management.

Purpose of the Study:

  • To report the clinical outcomes and health-care costs of a cohort of 413 patients with COPD.
  • To analyze the pharmacoeconomic impact of different bronchodilator therapies on total treatment costs stratified by COPD severity.

Main Methods:

  • Retrospective pharmacoeconomic analysis of 413 COPD patients meeting specific spirometric criteria (FEV(1) < 65% and FEV(1)/FVC < 70%).
  • Health-care resource utilization and costs were identified via chart review and stratified by COPD severity (ATS stages I, II, III).

Related Experiment Videos

  • Cost-of-illness evaluation included drug acquisition, oxygen therapy, tests, clinic visits, and emergency/hospitalizations.

    • Main Results:

    • Total treatment cost strongly correlated with COPD severity: Stage I ($1,681/yr), Stage II ($5,037/yr), and Stage III ($10,812/yr).
    • Hospitalization was the primary cost driver across all severity stages.
    • Ipratropium alone (Stage I) and ipratropium plus a ss-agonist (Stages II & III) demonstrated the lowest total costs, associated with reduced add-on drug use and fewer healthcare resource utilizations.

    Conclusions:

    • A significant correlation exists between COPD disease severity and total treatment costs.
    • Bronchodilator therapy choice impacts overall COPD costs, with specific regimens proving more cost-effective at different disease stages.
    • Adherence to published COPD treatment guidelines may lead to reduced healthcare expenditures.